Surrozen (SRZN) Total Current Liabilities (2020 - 2026)
Surrozen (SRZN) recorded quarterly Total Current Liabilities of $9.6 million in Q1 2026, down 3.68% quarter-over-quarter from $9.9 million in Q4 2025, and down 9.61% on a YoY basis from $10.6 million in Q1 2025.
Surrozen (SRZN) Total Current Liabilities (2020 - 2026) Analysis & Trends
Surrozen's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $9.6 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 9.61% year-over-year to $9.6 million; the TTM figure through Mar 2026 stood at $9.6 million (down 9.61% YoY), while the FY2025 annual figure was $9.9 million, up 35.75% from the prior year.
- Total Current Liabilities was $9.6 million for Q1 2026 at Surrozen, down from $9.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $10.6 million in Q1 2025 to a low of $5.7 million in Q2 2025.
- Historically, Total Current Liabilities has averaged $7.7 million across 5 years, with a median of $7.3 million in 2024.
- Biggest YoY gain for Total Current Liabilities was 722.53% in 2022; the steepest drop was 30.99% in 2022.
- A 5-year view of Total Current Liabilities shows it stood at $9.7 million in 2022, then fell by 26.55% to $7.1 million in 2023, then climbed by 2.34% to $7.3 million in 2024, then surged by 35.75% to $9.9 million in 2025, then fell by 3.68% to $9.6 million in 2026.
- The last three Total Current Liabilities figures came in at $9.6 million (Q1 2026), $9.9 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 13.42 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 72.86 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 9.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.57 Mn |
| Dec 31, 2025 | 9.93 Mn |
| Sep 30, 2025 | 6.53 Mn |
| Jun 30, 2025 | 5.74 Mn |
| Mar 31, 2025 | 10.58 Mn |
| Dec 31, 2024 | 7.32 Mn |
| Sep 30, 2024 | 6.12 Mn |
| Jun 30, 2024 | 5.98 Mn |
| Mar 31, 2024 | 6.18 Mn |
| Dec 31, 2023 | 7.15 Mn |
| Sep 30, 2023 | 6.67 Mn |
| Jun 30, 2023 | 6.45 Mn |
| Mar 31, 2023 | 7.79 Mn |
| Dec 31, 2022 | 9.73 Mn |
| Sep 30, 2022 | 8.65 Mn |
| Jun 30, 2022 | 8.52 Mn |
| Mar 31, 2022 | 8.12 Mn |
| Dec 31, 2021 | 13.57 Mn |
| Sep 30, 2021 | 12.54 Mn |
| Jun 30, 2021 | 1.54 Mn |